Harrow (HROW) Capital Expenditures Growth (5y) (2017 - 2026)
Harrow (HROW) Capital Expenditures Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.15 Bn | 20.99 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn |
| 10 | Harrow | 1.42 Bn | 1.32 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.67% |
| Dec 31, 2025 | 32.98% |
| Sep 30, 2025 | 11.26% |
| Jun 30, 2025 | -16.29% |
| Mar 31, 2025 | -5.03% |
| Dec 31, 2024 | 10.04% |
| Sep 30, 2024 | 40.84% |
| Jun 30, 2024 | -16.30% |
| Mar 31, 2024 | -16.01% |
| Dec 31, 2023 | -22.64% |
| Sep 30, 2023 | 17.31% |
| Jun 30, 2023 | -25.10% |
| Mar 31, 2023 | 20.90% |
| Dec 31, 2022 | 36.69% |
| Sep 30, 2022 | 31.73% |
| Jun 30, 2022 | 8.61% |
| Mar 31, 2022 | 21.92% |
| Sep 30, 2021 | -46.41% |
| Jun 30, 2021 | -27.52% |
| Mar 31, 2021 | -38.34% |